乳腺癌治疗后患者亚临床系统性淋巴水肿的患病率及其与体重指数的关系。
Prevalence of Subclinical Systemic Lymphedema in Patients Following Treatment for Breast Cancer and Association with Body Mass Index.
作者信息
Pereira de Godoy Jose Maria, Pereira de Godoy Lívia Maria, Guerreiro Godoy Maria de Fatima
机构信息
Cardiology and Cardiovascular Surgery, São José do Rio Preto School of Medicine (FAMERP), Sao Jose do Rio Preto, BRA.
Angiology and Vascular Surgery, The Godoy Clinic, Sao Jose do Rio Preto, BRA.
出版信息
Cureus. 2020 Mar 16;12(3):e7291. doi: 10.7759/cureus.7291.
The aim of the present study is to evaluate the prevalence of subclinical systemic lymphedema in patients with lymphedema following treatment for breast cancer and the association with the body mass index (BMI). A cross-sectional study was conducted to determine the prevalence of subclinical systemic lymphedema using bioelectrical impedance analysis in patients with lymphedema following treatment for breast cancer. One hundred women with lymphedema of the upper limbs resulting from treatment for breast cancer were evaluated at the Godoy Clinic in 2019. Fisher's exact test demonstrated a significant association between BMI higher than 30 kg/m and subclinical systemic lymphedema (p=0.01). The prevalence of subclinical systemic lymphedema is high among patients with lymphedema following treatment for breast cancer and is associated with the increase in BMI.
本研究的目的是评估乳腺癌治疗后发生淋巴水肿的患者中亚临床系统性淋巴水肿的患病率及其与体重指数（BMI）的关联。我们进行了一项横断面研究，以通过生物电阻抗分析确定乳腺癌治疗后发生淋巴水肿的患者中亚临床系统性淋巴水肿的患病率。2019年，在戈多伊诊所对100名因乳腺癌治疗导致上肢淋巴水肿的女性进行了评估。费舍尔精确检验表明，BMI高于30 kg/m与亚临床系统性淋巴水肿之间存在显著关联（p=0.01）。乳腺癌治疗后发生淋巴水肿的患者中亚临床系统性淋巴水肿的患病率较高，且与BMI升高有关。
Zotero 插件